5,650 XNAS Volume
XNAS 28 Mar, 2025 5:30 PM (EDT)
Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|
Dylan Hartley | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2025 | 45,000 | 45,000 | - | - | Employee Stock Option (right to buy) | |
Samuel Agresta | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2025 | 45,000 | 45,000 | - | - | Employee Stock Option (right to buy) | |
Jason A. Leverone | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2025 | 65,000 | 65,000 | - | - | Employee Stock Option (right to buy) | |
Nicholas A. Saccomano | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2025 | 130,000 | 130,000 | - | - | Employee Stock Option (right to buy) | |
Jason A. Leverone | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Oct 2024 | 130,611 | 130,611 | - | - | Employee Stock Option (right to buy) | |
Dylan Hartley | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Oct 2024 | 137,603 | 137,603 | - | - | Employee Stock Option (right to buy) | |
Valerie Malyvanh Jansen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Oct 2024 | 15,300 | 15,300 | - | - | Stock Option (right to buy) | |
Andrew Phillips | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Oct 2024 | 15,300 | 15,300 | - | - | Stock Option (right to buy) | |
Isaac Manke | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Oct 2024 | 15,300 | 15,300 | - | - | Stock Option (right to buy) | |
Samuel Agresta | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Oct 2024 | 18,588 | 18,588 | - | - | Employee Stock Option (right to buy) | |
Samuel Agresta | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Oct 2024 | 131,396 | 131,396 | - | - | Employee Stock Option (right to buy) | |
Jason A. Leverone | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Oct 2024 | 5,781 | 5,781 | - | - | Employee Stock Option (right to buy) | |
Jason A. Leverone | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Oct 2024 | 5,322 | 5,322 | - | - | Employee Stock Option (right to buy) | |
Edward T. Mathers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Oct 2024 | 15,300 | 15,300 | - | - | Stock Option (right to buy) | |
Jason A. Leverone | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Oct 2024 | 16,331 | 16,331 | - | - | Class A Common Stock | |
Nicholas A. Saccomano | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Oct 2024 | 8,449 | 8,449 | - | - | Employee Stock Option (right to buy) | |
Nicholas A. Saccomano | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Oct 2024 | 16,898 | 16,898 | - | - | Employee Stock Option (right to buy) | |
Nicholas A. Saccomano | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Oct 2024 | 1,485 | 1,485 | - | - | Employee Stock Option (right to buy) | |
Nicholas A. Saccomano | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Oct 2024 | 2,359 | 2,359 | - | - | Employee Stock Option (right to buy) | |
Nicholas A. Saccomano | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Oct 2024 | 4,556 | 4,556 | - | - | Class A Common Stock | |
Nicholas A. Saccomano | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Oct 2024 | 542,232 | 542,232 | - | - | Employee Stock Option (right to buy) | |
R. Michael Carruthers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Oct 2024 | 874 | 874 | - | - | Class A Common Stock | |
R. Michael Carruthers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Oct 2024 | 15,300 | 15,300 | - | - | Stock Option (right to buy) | |
R. Michael Carruthers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Oct 2024 | 1,324 | 1,324 | - | - | Stock Option (right to buy) | |
R. Michael Carruthers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Oct 2024 | 1,760 | 1,760 | - | - | Stock Option (right to buy) | |
R. Michael Carruthers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Oct 2024 | 4,065 | 4,939 | - | - | Class A Common Stock |